Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Overall, this study suggests that PK exhibits a neuroprotective effect by inducing alternative activation of microglia and downregulating the BACE1 expression, thereby ameliorating the disease pathophysiology and reversing the cognitive decline related to Aβ deposition in AD mice.
|
31741224 |
2020 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
Previous studies indicated that BACE1 initially cleaves the amyloid precursor protein (APP) and may subsequently interfere with physiological functions of proteins such as PKA, which is recognized to be closely associated with long-term potentiation (LTP) level and can effectively ameliorate cognitive impairments.
|
31223308 |
2019 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
Using this system to target Bace1 suppressed amyloid beta (Aβ)-associated pathologies and cognitive deficits in two mouse models of Alzheimer's disease.
|
30858603 |
2019 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
It has been hypothesised that partial inhibition of BACE1 in individuals with a high risk of developing Alzheimer's disease may be beneficial in preventing cognitive decline.
|
31547430 |
2019 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation.
|
30596903 |
2019 |
Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Depletion of NRF2 increases <i>BACE1</i> and <i>BACE1-AS</i> expression and Aβ production and worsens cognitive deficits.
|
31164420 |
2019 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
We found miR-361-3p inhibited β-amyloid accumulation by targeting BACE1, which thus weakened cognitive deficits in Alzheimer's disease.
|
31601077 |
2019 |
Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Hypomethylation of these enhancers in AD is associated with an upregulation of BACE1 transcripts and an increase in amyloid plaques, neurofibrillary tangles, and cognitive decline.
|
31113950 |
2019 |
Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Surprisingly, blocking GRs for only 3 days at 12 months of age reduced CORT levels, reduced hippocampal Aβ40 and -42, and β-site APP-cleaving enzyme 1 (BACE1) levels, and notably rescued the cognitive deficits in 12-month-old APPswe/PS1dE9 mice.
|
29491368 |
2018 |
Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Ng/BACE1 levels were elevated in both subjective cognitive decline and mild cognitive impairment compared to healthy controls.
|
30519627 |
2018 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
The senile plaques (SPs) in the brain are one of the most pathophysiological characteristics of cognitive dysfunction and its major constituent amyloid β (Aβ) released from amyloid precursor protein (APP) by β (BACE1) and γ (presenilin 1) secretases .
|
29775888 |
2018 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, so far pharmacological BACE1 inhibition failed to rescue the cognitive decline in mild-to-moderate AD patients, which indicates that treatment at the symptomatic stage might be too late.
|
29327084 |
2018 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
Chronic Sleep Restriction Induces Cognitive Deficits and Cortical Beta-Amyloid Deposition in Mice via BACE1-Antisense Activation.
|
28145081 |
2017 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, the lack of BACE1 S-palmitoylation mitigates cognitive deficits in 5XFAD mice.
|
29078331 |
2017 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
RGD |
Sleep deprivation accelerates the progression of alzheimer's disease by influencing Aβ-related metabolism.
|
28455102 |
2017 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
These data highlight the potential benefits of BACE inhibition for the effective treatment of a wide range of AD-like pathophysiological and cognitive impairments.
|
28739891 |
2017 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results indicate that DISC1 attenuates Aβ generation and cognitive deficits of APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1.
|
26062786 |
2016 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
|
25926467 |
2015 |
Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
It suggests that BACE1 overexpression-induced SET upregulation may contribute to growth delay and cognitive impairment in DS patients.
|
24935721 |
2015 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that chronic brain hypoperfusion (CBH) causes Aβ aggregation by upregulating expression of amyloid precursor protein (APP) and β-site APP cleaving enzyme 1 (BACE1) protein, which is accompanied by cognitive impairment, but the mechanisms are not fully understood.
|
23447608 |
2013 |
Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments.
|
22275252 |
2012 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment.
|
20505099 |
2010 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
We demonstrate that genetic reductions of both BACE1 and gamma-secretase additively attenuate the amyloid burden and ameliorate cognitive deficits occurring in aged APPswe/PS1DeltaE9 animals.
|
20371462 |
2010 |
Impaired cognition
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we used heterozygous BACE1 gene knockout (BACE1+/-) mice to evaluate the effects of partial BACE1 suppression on different types of synaptic and cognitive dysfunctions in Alzheimer's transgenic mice (5XFAD model).
|
20089133 |
2010 |
Impaired cognition
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We have recently shown that Alzheimer's disease (AD) transgenic mice given a moderate level of caffeine intake (the human equivalent of 5 cups of coffee per day) are protected from development of otherwise certain cognitive impairment and have decreased hippocampal amyloid-beta (Abeta) levels due to suppression of both beta-secretase (BACE1) and presenilin 1 (PS1)/gamma-secretase expression.
|
19581722 |
2009 |